Management of malignant pleural effusions

Current Opinion in Pulmonary Medicine

Volumn 17, Issue 4, 2011, Pages 269-273

  Rodriguez Panadero, Francisco ^a   Romero Romero, Beatriz ^a  

^a Instituto de Biomedicina de Sevilla   (Spain)

Author keywords

malignant pleural effusions; pleural catheters; pleurodesis; talc

Indexed keywords

ANTINEOPLASTIC AGENT; DOXYCYCLINE; GENE THERAPY AGENT; INTERLEUKIN 8; LIDOCAINE; POVIDONE IODINE; SCLEROSING AGENT; SILVER NITRATE;

BLOOD CLOTTING; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CATHETER; HUMAN; LOCAL ANESTHESIA; MALIGNANT PLEURA EFFUSION; PLEURA EFFUSION; PLEURA FLUID; PLEURODESIS; PNEUMONIA; RESPIRATORY DISTRESS; REVIEW; SURVIVAL RATE; SURVIVAL TIME; THORACOCENTESIS;

CATHETERS, INDWELLING; HUMANS; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS;

EID: 79958795094     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3283474015     Document Type: Review

References (53)

1. Roberts ME, Neville E, Berrisford RG, et al. BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65 (Suppl 2):ii32-40. Comprehensive review containing evidence-based recommendations for the management of malignant pleural effusions, with a very clear algorithm for management presented. Strongly recommended for the interested reader.
2. Uzbeck MH, Almeida FA, Sarkiss MG, et al. Management of malignant pleural effusions. Adv Ther 2010; 27:334-347. Good comprehensive review of both diagnostic and therapeutic issues in malignant pleural effusions (MPE). Pharmaceutical and nonpharmaceutical approaches to the management of MPE are analyzed, and a novel algorithm(rather complex, but complete) for management based on patients' performance status is included.
3. Mishra EK, Davies RJ. Advances in the investigation and treatment of pleural effusions. Expert Rev Respir Med 2010; 4:123-133.
4. Lombardi G, Zustovich F, Nicoletto MO, et al. Diagnosis and treatment of malignant pleural effusion: a systematic literature review and new approaches. Am J Clin Oncol 2010; 33:420-423.
5. Musani AI. Treatment options for malignant pleural effusion. Curr Opin Pulm Med 2009; 15:380-387.
6. Thai V, Damant R. Malignant pleural effusions: interventional management #157. J Palliat Med 2009; 12:1051-1052.
7. Heffner JE. Management of the patient with a malignant pleural effusion. Semin Respir Crit Care Med 2010; 31:723-733.
8. Jones DR, Taylor MD, Petroni GR, et al. Phase I trial of intrapleural docetaxel administered through an implantable catheter in subjects with a malignant pleural effusion. J Thorac Oncol 2010; 5:75-81. Although preliminary by nature and with only 15 patients with malignant pleural effusion (MPE) included, this phase I trial was remarkable in design and results: four single dose levels of docetaxel were administered intrapleurally after drainage of the malignant pleural effusion and insertion of an intrapleural catheter. The study determined the pharmacokinetic properties, clinical response, and toxicity profile of intrapleural docetaxel, and the majority of patients had a complete radiographic response.
9. Kimura M, Tojo T, Naito H, et al. Effects of a simple intraoperative intrathoracic hyperthermotherapy for lung cancer with malignant pleural effusion or dissemination. Interact Cardiovasc Thorac Surg 2010; 10:568-571.
10. Ozyurtkan MO, Balci AE, Cakmak M. Predictors of mortality within three months in the patients with malignant pleural effusion. Eur J Intern Med 2010; 21:30-34.
11. Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. Chest 2000; 117:79-86. (Pubitemid 30053624)
12. Sanchez-Armengol A, Rodriguez-Panadero F. Survival and talc pleurodesis in metastatic pleural carcinoma, revisited. Report on 125 cases. Chest 1993; 104:1482-1485. (Pubitemid 23327868)
13. Rodríguez-Panadero F, Del Rey Pérez JJ. Survival of malignant pleural mesotheliomas as compared to metastatic carcinomas. Eur Respir Rev 1993; 3:208-210. (Pubitemid 23135375)
14. Huggins JT, Doelken P, Sahn SA. The unexpandable lung. F1000 Med Rep 2010; 2:77. In this interesting work the authors differentiate between 'trapped lung' (caused by a benign fibrotic peel covering the visceral pleura and provoking mechanical problems) and 'lung entrapment', which would be secondary to active pleural inflammation, infection, or malignancy. In these cases, the underlying malignant or inflammatory condition is the primary clinical problem, and placement of a chronic indwelling catheter should be considered if the effusion is malignant. Pleural manometry was performed routinely during therapeutic thoracentesis and was useful for identification of different conditions leading to unexpandable lung.
15. Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 2004; 1:CD002916.
16. Tan C, Sedrakyan A, Browne J, et al. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg 2006; 29:829-838.
17. Dresler CM, Olak J, Herndon JE, et al. Phase III intergroup study of talc poudrage vs. talc slurry sclerosis for malignant pleural effusion. Chest 2005; 127:909-915. (Pubitemid 40775523)
18. Mañes N, Rodriguez-Panadero F, Bravo JL, et al. Talc pleurodesis: prospective and randomized study. Clinical follow-up. Chest 2000; 118 (4 Suppl):131S.
19. Rodriguez-Panadero F, Jannsen JP, Astoul P. Thoracoscopy: general overview and place in the diagnosis and management of pleural effusion. Eur Respir J 2006; 28:409-421. (Pubitemid 44920002)
20. Neto JD, de Oliveira SF, Vianna SP, Terra RM. Efficacy and safety of iodopovidone pleurodesis in malignant pleural effusions. Respirology 2010; 15:115-118.
21. Mohsen TA, Zeid AA, Meshref M, et al. Local iodine pleurodesis versus thoracoscopic talc insufflation in recurrent malignant pleural effusion: a prospective randomized control trial. Eur J Cardiothorac Surg 2010 [Epub ahead of print]. Prospective randomized study including 42 patients with metastatic breast cancer. All patients were submitted to diagnostic thoracoscopy (using general anesthesia and double-lumen tracheal intubation), and then randomized to receive either talc poudrage at the end of the thoracoscopy procedure (group A) or bedside instillation of 20 ml of 10% povidone - iodine mixed with 30 ml of normal saline through the intercostal chest drain (group B). Two patients out of 22 in group A (9%) and 3 out of 20 (15%) in group B had a recurrence of the effusion requiring therapeutic measures during follow-up [mean: 22.6 (range: 8-48) months]. The authors conclude that povidone-iodine can be considered as a good alternative to thoracoscopic talc poudrage to ensure effective pleurodesis for patients with malignant pleural effusion due to metastatic breast cancer. Although the difference in outcome of pleurodesis was not significant, there was a tendency in favor of talc.
22. Terra RM, Kim SY, Pego-Fernandes PM, et al. Is silver nitrate pleurodesis for patients with malignant pleural effusion feasible and safe when performed in an outpatient setting? Ann Surg Oncol 2010 [Epub ahead of print]. In a prospective study, pleurodesis using silver nitrate was performed in an outpatient basis. A total of 70 procedures were done on 63 patients with recurrent malignant pleural effusion, and results were evaluated at 30 days postprocedure. Two recurrences among 48 evaluable procedures were observed at this time and, in spite of acute pain in a significant number of patients, improvement of quality of life was noted at follow-up in most of them.
23. Porcel JM, Salud A, Nabal M, et al. Rapid pleurodesis with doxycycline through a small-bore catheter for the treatment of metastatic malignant effusions. Support Care Cancer 2006; 14:475-478.
24. Bosch-Barrera J, Espinós J. Hepatic breast cancer dissemination after an iatrogenic hepatic laceration during talc pleurodesis: a case report. Int Arch Med 2010; 3:6.
25. Rinaldo JE, Owens GR, Rogers RM. Adult respiratory distress syndrome following intrapleural instillation of talc. J Thorac Cardiovasc Surg 1983; 85:523-526. (Pubitemid 13091283)
26. Rehse DH, Aye RW, Florence MG. Respiratory failure following talc pleurodesis. Am J Surg 1999; 177:437-440. (Pubitemid 29252818)
27. Maskell NA, Lee YC, Gleeson FV, et al. Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med 2004; 170:377-382. (Pubitemid 39214610)
28. Milanez de Campos JR, Campos Werebe E, Vargas FS, et al. Respiratory failure due to insufflated talc. Lancet 1997; 349:251-252. (Pubitemid 27050994)
29. Ferrer J, Villarino MA, Tura JM, et al. Talc preparations used for pleurodesis vary markedly from one preparation to another. Chest 2001; 119:1901-1905. (Pubitemid 32744951)
30. Jannsen JP, Collier G, Astoul P, et al. Safety of talc poudrage in malignant pleural effusion. Lancet 2007; 369:1535-1539.
31. Gonzalez AV, Bezwada V, Beamis JF Jr, Villanueva AG. Lung injury following thoracoscopic talc insufflation: experience of a single North American center. Chest 2010; 137:1375-1381. Detailed study on 142 thoracoscopic talc poudrages performed in 138 patients, with careful analysis of data and excellent discussion providing insights on possible factors related to complications associated with talc pleurodesis.
32. Barbetakis N, Asteriou C, Papadopoulou F, et al. Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases. J Cardiothorac Surg 2010; 5:27.
33. Kennedy L, Harley RA, Sahn SA, Strange C. Talc slurry pleurodesis: pleural fluid and histologic analysis. Chest 1995; 107:1707-1712.
34. Montes-Worboys A, Rodriguez-Portal JA, Arellano-Orden E, et al. Interleukin-8 activates coagulation and correlates with survival after talc pleurodesis. Eur Respir J 2010; 35:160-166. In this prospective study, IL-8 and tumor necrosis factor-alpha were measured in plasma samples from 231 patients with MPE before and after talc pleurodesis. Whole blood from 31 healthy volunteers was also incubated with IL-8, TNF-alpha and thromboplastin in vitro, and thrombin-antithrombin (TAT) levels were measured. The same stimulation of blood samples was repeated using doses of calibrated talc. Survival correlated inversely with IL-8 at 24 and 48 h in serum, and a significant correlation was also found between serum IL-8 and TAT levels. A positive dose-dependent correlation with TAT production was observed when blood was stimulated with IL-8 in vitro. It is concluded that IL-8 is involved in the activation of coagulation that may occur after talc pleurodesis, and might also be implicated in early death of patients with MPE.
35. Cafarotti S, Dall'armi V, Cusumano G, et al. Small-bore wire-guided chest drains: safety, tolerability and effectiveness in pneumothorax, malignant effusions, and pleural empyema. J Thorac Cardiovasc Surg 2011; 141:683-687.
36. Liu YH, Lin YC, Liang SJ, et al. Ultrasound-guided pigtail catheters for drainage of various pleural diseases. Am J Emerg Med 2010; 28:915-921.
37. Van Meter ME, McKee KY, Kohlwes RJ. Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review. J Gen Intern Med 2011; 26:70-76. Systematic review on TPCs, with search methodology well described and clear inclusion and exclusion criteria. Patients with poor life expectancy and presence of lung entrapment are good candidates for TPC placement, always requiring good home supportive care.
38. Olden AM, Holloway R. Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? A cost-effectiveness analysis. J Palliat Med 2010; 13:59-65. Extensive decision analysis to compare treatments for the management of MPE was used in this study. Treatment with talc was less costly than TPC, with similar effectiveness. TPC became more cost effective when life expectancy was 6 weeks or less.
39. Thornton RH, Miller Z, Covey AM, et al. Tunneled pleural catheters for treatment of recurrent malignant pleural effusion following failed pleurodesis. J Vasc Interv Radiol 2010; 21:696-700.
40. Schneider T, Reimer P, Storz K, et al. Recurrent pleural effusion: who benefits from a tunneled pleural catheter? Thorac Cardiovasc Surg 2009; 57:42-46.
41. Cases E, Seijo L, Disdier C, et al. Use of indwelling pleural catheter in the outpatient management of recurrent malignant pleural effusion. Arch Bronconeumol 2009; 45:591-596. In this multicenter study including 63 consecutive patients with MPE, a tunneled pleural catheter was inserted on an outpatient basis. Most of the patients (94.5%) reported an improvement in their respiratory symptoms (cough and dyspnea), and spontaneous pleurodesis was achieved following 34.9% of procedures. Empyema was observed in three cases, persistent chest pain in two, and tumor metastasis in three patients. (Article published both in Spanish and English).
42. Efthymiou CA, Masudi T, Thorpe JA, Papagiannopoulos K. Malignant pleural effusion in the presence of trapped lung. Five-year experience of PleurX tunneled catheters. Interact Cardiovasc Thorac Surg 2009; 9:961-964.
43. Reddy C, Ernst A, Lamb C, Feller-Kopman D. Rapid pleurodesis for malignant pleural effusions: a pilot study. Chest 2010 [Epub ahead of print].
44. Sioris T, Sihvo E, Salo J, et al. Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis. Eur J Surg Oncol 2009; 35:546-551.
45. Janes SM, Rahman NM, Davies RJ, Lee YC. Catheter-tract metastases associated with chronic indwelling pleural catheters. Chest 2007; 131:1232-1234. (Pubitemid 46608729)
46. Morel A, Mishra E, Medley L, et al. Chemotherapy should not be withheld from patients with an indwelling pleural catheter for malignant pleural effusion. Thorax 2010 [Epub ahead of print].
47. Stathopoulos GT. Translational advances in pleural malignancies. Respirology 2010. doi: 10.1111/j.1440-1843.2010.01890.x. [Epub ahead of print]. Excellent revision on recent basic studies with probable translation into clinical advances in a few years ahead. We recommend it to the interested reader.
48. Lee P, Sun L, Lim CK, et al. Selective apoptosis of lung cancer cells with talc. Eur Respir J 2010; 35:450-452.
49. Nasreen N, Mohammed KA, Dowling PA, et al. Talc induces apoptosis in human malignant mesothelioma cells in vitro. Am J Respir Crit Care Med 2000; 161:595-600. (Pubitemid 30129472)
50. Sterman DH, Recio A, Haas AR, et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther 2010; 18:852-860.
51. Watanabe M, Boyer JL, Crystal RG. AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors. Gene Ther 2010; 17:1042-1051.
52. Jian G, Songwen Z, Ling Z, et al. Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced nonsmall cell lung cancer. J Cancer Res Clin Oncol 2010; 136:1341-1347.
53. Basak SK, Veena MS, Oh S, et al. The malignant pleural effusion as a model to investigate intratumoral heterogeneity in lung cancer. PLoS One 2009; 4:e5884. A very promising field of research has been open in this study by establishing malignant pleural effusion as a model to investigate intratumoral heterogeneity in lung cancer, with subsequent differences in response to treatment.